Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABS), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.
SAB Biotherapeutics, Inc. (Nasdaq: SABS), or SAB BIO, generates frequent news as a clinical-stage biopharmaceutical company advancing fully human immunoglobulin G (hIgG) and human anti-thymocyte immunoglobulin (hATG) therapies for immune and autoimmune disorders. Most recent headlines focus on SAB-142, the company’s multi-specific, fully human anti-thymocyte globulin in development as a potentially disease-modifying, redosable immunotherapy for autoimmune type 1 diabetes (T1D) in new-onset, Stage 3 patients.
News updates commonly cover clinical milestones for SAB-142, including Phase 1 trial results and the launch and progress of the Phase 2b registrational SAFEGUARD study. Releases describe safety, pharmacodynamic, and immunogenicity findings, such as the absence of serum sickness and anti-drug antibodies in the Phase 1 trial, as well as the design and enrollment status of the SAFEGUARD trial at multiple centers around the world.
SABS news also highlights SAB BIO’s scientific presence at major medical meetings. The company regularly announces oral and poster presentations at conferences such as the European Association for the Study of Diabetes (EASD), the International Society for Pediatric and Adolescent Diabetes (ISPAD), and the Asian Conference on Innovative Therapies for Diabetes Management. These items detail new data on SAB-142’s mechanism of action, immunomodulatory effects without sustained lymphodepletion, and pharmacokinetic profiling.
Investors and observers will also find corporate and investor-relations updates, including participation in healthcare investor conferences and changes to the Board of Directors, as well as summaries of quarterly financial results and business highlights. For anyone tracking SABS, this news feed provides an ongoing view into SAB BIO’s clinical development progress, scientific communications, governance developments, and key events related to its lead program SAB-142 and its broader human IgG platform.
SAB Biotherapeutics (SABS) has been added to the NASDAQ Biotechnology Index effective December 20, 2021. This index tracks biotech and pharmaceutical firms listed on Nasdaq that meet specific criteria, including market cap. SAB, a clinical-stage biopharmaceutical company, focuses on immunotherapy development using fully-human polyclonal antibodies without human donors. The inclusion in the index may enhance visibility and liquidity for shareholders, and reflects its compliance with industry standards.
SAB Biotherapeutics (Nasdaq: SABS) announced that its therapeutic candidate, SAB-185, effectively neutralizes the Omicron variant of SARS-CoV-2, according to FDA laboratory testing. This confirmation comes as SAB-185 progresses through a NIH-sponsored Phase 3 trial aimed at treating COVID-19. The results show that SAB-185 maintains potent neutralization against Omicron, although with a slight reduction in efficacy compared to the original strain. The ongoing trial includes around 1,200 participants to evaluate the safety and effectiveness of this fully-human polyclonal antibody.
SAB Biotherapeutics announced positive topline results from a Phase 2a challenge study of SAB-176, showing a statistically significant reduction in viral load (p = 0.026) and clinical symptoms for seasonal influenza. The treatment was safe and well-tolerated among participants. This achievement marks the second clinical proof of concept for the company's DiversitAb™ platform within two months, further emphasizing its ability to generate broadly neutralizing antibodies against rapidly mutating viruses. Plans are underway to progress SAB-176 into a Phase 2 trial starting in 2Q 2022.
SAB Biotherapeutics announced key advancements in its pipeline, including the progression of SAB-185 to Phase 3 in the NIH-sponsored ACTIV-2 Trial for COVID-19 after a positive recommendation from the Data Safety Monitoring Board. The company also secured an additional $60.5 million from the Department of Defense for the continued development of SAB-185, bringing total funding since March 2020 to over $203 million. Financial results reveal a cash position of $30 million post-business combination, but a net loss of $5.6 million for 2021, compared to a net income of $11.7 million in 2020.
SAB Biotherapeutics announced the completion of its business combination with Big Cypress Acquisition Corp., with shares commencing trading on Nasdaq under the ticker symbols SABS and SABSW on October 25, 2021. The transaction received approval from both companies' shareholders, resulting in gross proceeds of approximately $30 million. SAB aims to utilize these funds to advance its clinical programs, including those related to COVID-19 and influenza, and has secured an additional $60.5 million government award. SAB is focused on developing its unique DiversitAb™ immunotherapy platform.